Watch our latest webinar, a valuable resource for clinicians navigating the complex decisions surrounding autologous transplant and chimeric antigen receptor T cell therapy.
Expert Madiha Iqbal, Consultant and Assistant Professor of Medicine, Mayo Clinic, Jacksonville, Florida, USA, presents on the treatment landscape for large B-cell lymphoma, and discusses the advantages and limitations of these two approaches for both clinicians and patients.
Themes covered include:
- the paradigm shift in large B-cell lymphoma;
- limitations of haematopoietic cell transplant, and the evolution of chimeric antigen receptor T cell therapy; and
- how to approach chimeric antigen receptor T cell therapy compared to autologous haematopoietic cell transplant in large B-cell lymphoma.
Speaker:
Madiha Iqbal is a Consultant and an Assistant Professor of Medicine in the Division of Hematology/Oncology at the Mayo Clinic, Jacksonville, Florida. She trained at the Mayo Clinic for a fellowship in haematology and oncology, and served as the chief fellow for her class. She has been a member of the Graduate Education Committee, and serves as the educational chair for the Mayo Fellows Association. She is extremely active in clinical research, and has published multiple manuscripts in high impact journals. Her clinical and research focus is in cellular therapies, namely hematopoietic cell transplantation and chimeric antigen receptor T cell therapy. From a disease interest standpoint, her focus is on lymphoma. She is the principal investigator for multiple interventional clinical trials investigating novel therapeutics for patients with lymphomas, and those receiving haematopoietic cell transplant and chimeric antigen receptor T-cell therapy.
